What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional Class A common stock shares.
Simultaneously, Sanofi has agreed to invest $25.0 million in a concurrent private placement, purchasing either Class A or non-voting Class B common stock at the same price as the public offering. Leerink Partners and Oppenheimer & Co. Inc. are serving as joint bookrunners for the offering and placement agents for the private placement.
The proceeds will be used to advance Immuneering's preclinical and clinical product development and for general corporate purposes. The offering is subject to market conditions, and the private placement is contingent upon the offering's closing.
- Strategic $25.0 million investment commitment from Sanofi indicates strong institutional backing
- Proceeds will strengthen development pipeline and advance clinical programs
- Offering includes 30-day option for underwriters to purchase additional 15% shares, providing flexibility for increased capital raise
- Potential dilution for existing shareholders through new share issuance
- Private placement contingent on offering completion creates execution risk
- Market conditions may affect offering success and final terms
PepGen (Nasdaq: PEPG) announced groundbreaking clinical data from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) treatment. The company's drug candidate PGN-EDODM1 achieved a remarkable 53.7% mean splicing correction at 15 mg/kg dosing - the highest ever reported in DM1 patients.
The trial demonstrated 100% patient response rate with improved splicing correction. Safety data showed the treatment was generally well-tolerated, with only mild or moderate adverse events. The company previously reported 12.3% and 29.1% splicing correction at 5 mg/kg and 10 mg/kg doses respectively, showing greater than dose-proportional increases.
PepGen plans to report results from its multiple ascending dose (MAD) study's first cohort in Q1 2026.
- Achieved highest-ever 53.7% mean splicing correction in DM1 patients
- 100% of patients showed improved splicing correction at 15 mg/kg dose
- Greater than dose-proportional increases in both splicing correction and muscle tissue concentrations
- Generally well-tolerated safety profile with no serious treatment-related adverse events
- One patient experienced dose-limiting toxicity with kidney biomarker elevation
- Next study results not expected until Q1 2026
PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular and neurological diseases, has announced a proposed public offering of common stock and pre-funded warrants.
The offering includes shares of common stock and pre-funded warrants for certain investors, with a 30-day option for underwriters to purchase additional shares. Leerink Partners and Stifel are serving as joint book-running managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and general corporate purposes.
- Proceeds will support ongoing clinical trials and research development
- Company has secured prominent underwriters (Leerink Partners and Stifel)
- Offering includes flexibility with pre-funded warrants for certain investors
- Potential dilution for existing shareholders
- Timing and terms of the offering remain uncertain
- Additional share sales could pressure stock price
AtlasClear Holdings (NYSE American: ATCH) has successfully completed its previously announced $5 million financing through promissory notes, with the final $2 million closing led by board members. The notes were issued with a 20% Original Issue Discount, resulting in an aggregate principal amount of $6.25 million.
Board member Sandip Patel invested $1 million and will join as CFO and General Counsel. Sixth Borough Capital added $450,000, bringing their total investment to $950,000. The notes mature in six months or upon completion of a $10 million qualified equity financing, with conversion options at the qualified financing price.
The company will file its 10-K by September 29, 2025, followed by an earnings call on September 30, 2025 at 8:30 AM ET.
- Strong leadership confidence demonstrated by Board members' personal investments
- Successful completion of $5 million financing with $6.25 million aggregate principal amount
- Addition of experienced executive Sandip Patel as CFO and General Counsel
- Reported strong operating earnings from wholly owned subsidiary
- Material improvement in balance sheet and stockholders' equity
- 20% Original Issue Discount on notes increases effective cost of capital
- Short-term maturity of six months on promissory notes
- Potential dilution risk if notes convert to equity in future financing
22nd Century Group (Nasdaq: XXII) has secured a $9.5 million cash settlement from insurers for business interruption claims related to the November 2022 Grass Valley incident. The settlement payment must be made within 45 days of the agreement's effective date.
The company, now debt-free, views this non-dilutive capital as crucial for growth rather than survival. CEO Larry Firestone emphasized that after addressing legacy issues over the past 22 months, the company is positioned to achieve profitability in 2026.
22nd Century Group specializes in tobacco harm reduction through its proprietary non-GMO reduced nicotine tobacco plants, which contain 95% less nicotine than traditional tobacco. Their flagship product, VLN® cigarette, is the only FDA-authorized low nicotine combustible cigarette in the United States.
- None.
- Extended timeline to profitability (not until 2026)
- Settlement payment subject to 45-day payment timeline
- Previous business interruption indicates operational risks
TNF Pharmaceuticals (NASDAQ:TNFA) announced its corporate rebranding to Q/C Technologies and will trade under the new ticker symbol QCLS effective September 25, 2025. The name change reflects the company's strategic pivot from pharmaceuticals to quantum-class computing, following its acquisition of exclusive global rights to LightSolver's light-speed laser processing unit (LPU) for cryptocurrency applications.
The LPU technology offers significant advantages including 90% reduction in energy consumption compared to traditional systems while delivering superior performance to both GPUs and quantum computing. The company will continue evaluating strategic options for its legacy therapeutic programs, isomyosamine and Supera-CBD, as it transitions into blockchain infrastructure.
- Exclusive global rights to LightSolver's innovative LPU technology for cryptocurrency applications
- Technology reduces energy consumption by 90% while outperforming traditional GPUs
- Positions company in trillion-dollar blockchain infrastructure industry
- Retains potential value from legacy pharmaceutical assets
- Complete departure from established pharmaceutical business model
- Execution risk in transitioning to an entirely new industry
- Uncertain timeline for monetization of legacy pharmaceutical assets
uniQure (NASDAQ: QURE), a gene therapy company, has announced a proposed $200 million public offering of ordinary shares and pre-funded warrants. The company will grant underwriters a 30-day option to purchase additional shares up to 15% of the total offering.
The offering will be managed by Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities as bookrunning managers. The securities will be offered through uniQure's automatically effective shelf registration statement, with a preliminary prospectus supplement and accompanying prospectus to be filed with the SEC.
- Potential to strengthen balance sheet with $200 million capital raise
- Automatically effective shelf registration statement already in place
- Support from multiple prominent investment banks as bookrunners
- Potential dilution for existing shareholders
- Offering size represents significant portion of market cap
- Stock price may face pressure due to increased share supply
Hertz (NASDAQ: HTZ) has announced plans to offer $250 million in Exchangeable Senior Notes due 2030, with an additional option for purchasers to acquire up to $37.5 million more. The notes, issued by The Hertz Corporation, will be exchangeable into cash, common stock, or a combination thereof.
The company will use the proceeds to fund capped call transactions and partially redeem outstanding Senior Notes due 2026. The notes will bear semi-annual interest starting April 1, 2026, and mature on October 1, 2030. Pershing Square Capital Management plans to enter into $100 million swap transactions related to HTZ common stock, while CK Amarillo has expressed interest in purchasing up to $25 million of the notes.
- Opportunity to refinance and restructure debt obligations
- Implementation of capped call transactions to protect against potential dilution
- Strong institutional interest with Pershing Square and CK Amarillo participation
- Flexible exchange options into cash, stock, or combination thereof
- Additional debt burden with new $250 million notes offering
- Potential dilution risk for existing shareholders if notes are converted to stock
- Complex derivative transactions could impact stock price volatility
- Early redemption restrictions until October 6, 2028
Transocean (NYSE: RIG) has announced a significant public offering of 100 million shares with an additional 30-day option for underwriters to purchase up to 15 million additional shares. The offering, jointly managed by Citigroup and Morgan Stanley, aims to use the proceeds primarily for debt management, specifically targeting the repayment or redemption of a portion of the $655 million 8.00% Senior Notes due February 2027.
The offering is being conducted under a shelf registration statement that became effective on July 1, 2024. Any remaining proceeds will be allocated to general corporate purposes. The completion of the offering remains subject to market conditions and SEC review.
- Potential reduction of high-interest debt burden through refinancing of 8.00% Senior Notes
- Strategic debt management initiative to improve capital structure
- Strong institutional backing with Citigroup and Morgan Stanley as joint book-runners
- Significant shareholder dilution with 100 million new shares being offered
- Additional potential dilution through 15 million share underwriter option
- Large offering size indicates substantial capital needs